Dichloroacetic acid (DCA) is a chlorination byproduct found in finished drinking water. When administered in drinking water this chemical has been shown to produce hepatocellular adenomas and carcinomas in B6C3F1 mice over the animal's lifetime. In this study, we investigated whether mutant frequencies were increased in mouse liver using treatment protocols that yielded significant tumor induction. DCA was administered continuously at either 1.0 or 3.5 g/l in drinking water to male transgenic B6C3F1 mice harboring the bacterial lacI gene. Groups of five or six animals were killed at 4, 10 or 60 weeks and livers removed. At both 4 and 10 weeks of treatment, there was no significant difference in mutant frequency between the treated and control animals at either dose level. At 60 weeks, mice treated with 1.0 g/l DCA showed a 1.3-fold increase in mutant frequency over concurrent controls (P ϭ 0.05). Mice treated with 3.5 g/l DCA for 60 weeks had a 2.3-fold increase in mutant frequency over the concurrent controls (P ϭ 0.002). The mutation spectrum recovered from mice treated with 3.5 g/l DCA for 60 weeks contained G:C→A:T transitions (32.79%) and G:C→T:A transversions (21.31%). In contrast, G:C→A:T transitions comprised 53.19% of the recovered mutants among control animals. Although only 19.15% of mutations among the controls were at T:A sites, 32.79% of the mutations from DCA-treated animals were at T:A sites. This is consistent with the previous observation that the proportion of mutations at T:A sites in codon 61 of the H-ras gene was increased in DCA-induced liver tumors in B6C3F1 mice. The present study demonstrates DCA-associated mutagenicity in the mouse liver under conditions in which DCA produces hepatic tumors.
Introduction
The introduction of chlorine into public drinking water supplies has produced a dramatic decrease in water-borne disease outbreaks. Studies done in the 1970s revealed that chlorine can react with the humic and fulvic acids found in surface water, forming potentially toxic chlorinated byproducts (1) . Dichloroacetic acid (DCA*) is a major byproduct of this reaction, with concentrations in finished drinking water ranging from 33 to 160 µg/l (1) . Recently several studies, have demonstrated that DCA administered in drinking water *Abbreviations: DCA, dichloroacetic acid; X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactoside.
is a hepatocarcinogen in rodents (2) (3) (4) . From these studies, it appears that DCA is acting as a complete carcinogen, although its mechanism of action in the liver is unclear.
Because DCA is a volatile liquid, it is unsuited for evaluation in the standard Salmonella assay, where it is negative (5) . However, it is weakly mutagenic in Salmonella strain TA100 when tested in the vapor state (6) . DCA has also been shown to be an inducer of prophage λ in Escherichia coli in the microscreen prophage induction assay (6) . Although conflicting results were obtained when DCA was examined for its ability to induce DNA strand breaks (7, 8) , DCA was a weak inducer of chromosomal damage in the mouse in vivo under conditions that also produced tumors (9) .
To investigate further the mutagenicity of DCA in vivo, we used the Big Blue ® transgenic mouse mutagenesis assay to determine the mutant frequency and mutation spectrum in liver of B6C3F1 mice exposed to DCA for 4, 10 and 60 weeks (10) . The basis for this assay is the presence of a lacI target gene stably integrated into the mouse genome. The lacI gene is a recoverable target that is easily evaluated for in vivo mutagenesis. This assay offers the advantage of allowing for metabolic activation and detoxification of a chemical in a whole animal system, as well as making it simple to detect induced mutations. The experimental conditions used in this study, such as ad libitum exposure to food and drinking water and the concentrations of DCA in the drinking water, were identical to those used in previous chronic exposure cancer studies (2) .
Materials and methods

Treatment of animals
Male B6C3F1 [λ LIZ:C57BL/6(LIZ) femaleϫC3H male] were obtained from Stratagene (La Jolla, CA). Animals were~8-9 weeks old at the time of dosing. Animals were housed one per cage and cared for in a facility accredited by the American Association for the Accreditation of Laboratory Animal Care. The light cycle was 12 h light/12 h dark. Water consumption and weights were measured once a month. Five or six animals were assigned randomly to each treatment group. DCA (CAS no. 79-43-6; Aldrich Chemical Co., Milwaukee, WI) was administered ad libitum in deionized water at doses of either 3.5 or 1.0 g/l for 4, 10 or 60 weeks. The pH was adjusted to 6.8-7.2 by addition of sodium hydroxide. Control mice were given deionized water ad libitum. At each time point animals were killed by asphyxiation with CO 2 and cervical dislocation. Livers were removed, quick frozen in liquid nitrogen and stored at -80°C until DNA isolation.
Isolation and packaging of DNA Whole livers were homogenized in buffer (1.75 g/l Na 2 PO 4 , 8.0 g/l NaCl, 0.2 g/l KH 2 PO 4 , 10 mM Na 2 EDTA, pH 8.0) and stored in aliquots proportional to 100 mg tissue at -80°C. Upon removal of livers from animals treated with DCA for 60 weeks, visible nodules and tumors were excised from surrounding tissue. Only visually normal tissue was used in this analysis. Genomic DNA was isolated from homogenized liver aliquots by digestion with proteinase K, followed by phenol/chloroform extraction and ethanol precipitation. Livers from mice exposed to DCA for 60 weeks exhibited hypertrophy that was accompanied by glycogen deposition. Due to the high glycogen content of livers exposed to DCA, the following modification was added to the genomic DNA isolation method. Before ethanol precipitation of the DNA the upper aqueous phase was collected and dialyzed overnight at room temperature against 1ϫ TE (10 mM Tris-HCl, 1mM Na 2 EDTA, pH 7.5). The next day the 1ϫ TE was changed every 3-4 h, followed by a final dialysis overnight at room temperature. The dialyzed DNA was collected and stored at 4°C. As DNA was needed for packaging, 1 ml dialyzed DNA was precipitated with room temperature ethanol. The resulting DNA pellet was resuspended in 1ϫ TE and allowed to stand at room temperature for 24 h before storage at 4°C. The λ vector was recovered as phage particles by mixing the genomic DNA with λ packaging extracts in vitro (Transpack™; Stratagene). The phage particles were assayed for lacI -mutations by infecting E.coli strain SCS-8 for 15 min at 37°C, mixing with prewarmed LB ϩ MgSO 4 top agarose (10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl, 2 g/l MgSO 4 ·7H 2 O, 7 g/l agarose) containing 0.5 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal; Biosynth International, Naperville, IL) and pouring onto 25 cm-sided assay trays containing LB ϩ MgSO 4 agar. After an overnight incubation at 37°C plates were examined for the presence of blue mutant plaques on a background of colorless non-mutant plaques. Blue lacI -plaques were isolated as agarose plugs, eluted into SM buffer and plated at low density in order to verify phenotype and purify the mutant clone. Mutant frequencies were expressed as the number of confirmed blue plaques divided by the total number of plaques. The total number of plaques was determined by counting five representative square regions of each plate and multiplying the average count by a factor proportional to the total plate area.
In preliminary experiments, we noted that NZ amine medium with 1.5 mg/ml X-gal, as used by other investigators working with this system, resulted in the formation of a pale blue background on the plates. This blue background made detection of all but the darkest blue mutants difficult. The use of LB ϩ MgSO 4 medium with 0.5 mg/ml X-gal alleviated the high background yet still allowed for easy detection of mutant plaques that were a much paler blue than the color control λ strain CM0.
DNA sequence analysis
Mutants for sequencing were selected from treated animals and control animals at the 60 week time point. Ten mutants were sequenced from each animal, except in cases where this number of mutants was not available. One microliter of SM buffer containing resuspended mutant phage particles was spotted on a section of a LB ϩ MgSO 4 agar plate already overlaid with top agarose containing SCS-8 cells and X-gal. The plates were kept at room temperature until the applied spot of phage suspension was dry and then the plate was incubated overnight at 37°C. This resulted in a single large plaque of mutant phage. A portion of the top agarose from this 'megaplaque' was scraped with a sterile pipet tip, placed in a tube with 50 µl HPLC water and heated for 10 min in either a boiling water bath or at 99°C in a thermocycler. The boiled preparation was centrifuged to pellet bacterial debris; 2 µl supernatant was used per PCR reaction. The resulting product was purified using a JETpure PCR product purification kit (Genomed, Inc., RTP, NC) and then sequenced with a Taq DyeDeoxy Terminator cycle sequencing kit on an Applied Biosystems 373A DNA sequencer (Applied Biosystems, Inc., Foster City, CA). Sequence data were analyzed utilizing SeqEd™ software (Applied Biosystems, Inc.). Oligonucleotide primers used for PCR were 5Ј-CGG-GCCTCTTCGCTATT-3Ј and 5Ј-TCCTGCGTTATCCCCTG-3Ј. Primers used for DNA sequencing were 5Ј-CCGTATTACCGCCATGC-3Ј, 5Ј-CCATGAA-GACGGTACGC-3Ј, 5Ј-CCACACAACATACGAGC-3Ј, 5Ј-CAGACGCGCC-GAGACAG-3Ј and 5Ј-GGGGATGTGCTGCAAGG-3Ј. All primers were synthesized by Operon Technologies, Inc. (Alameda, CA).
Statistical analysis
Analyses of the statistical significance of increases in mutant frequency were performed using the generalized Cochran-Armitage test (11, 12) using the COCHARM program written by Troy D.Johnson. Comparison of mutation spectra was performed using the hypergeometric test as implemented in the program HG-PUBL (13).
Results
Mutant frequency in mouse liver
The mutant frequencies observed in the control and DCAtreated animals are summarized in Table I . A 2.34-fold increase in mutant frequency was observed in the liver of mice given 3.5 g/l DCA for 60 weeks. The mice receiving 1.0 g/l DCA for the same length of time showed a 1.33-fold increase in mutant frequency relative to the control value. There was no significant increase in mutant frequency relative to the control values for those mice treated for 4 or 10 weeks at either dose level. However, the mean mutant frequency for the control group at 10 weeks was relatively high, largely due to one animal that displayed a mutant frequency of 8.08ϫ10 -5 . The increases in mutant frequency over time following treatment with DCA at 3.5 g/l exhibit a highly significant trend overall (P ϭ 0.001), with both 10 and 60 week mutant frequencies significantly increased relative to the frequency at 4 weeks (P ϭ 0.04 and 0.002 respectively). Table II shows the classification of mutations found in control mice and mice treated with 3.5 g/l DCA for 60 weeks. This treated group was selected for sequence analysis because it showed the highest induced mutant frequency, thereby minimizing the presence of background mutants in the DCAinduced spectrum. The proportions of specific mutation types recovered are significantly different (P ϭ 0.05, hypergeometric test) for control and DCA-treated mice. When the mutation frequency is adjusted for possible 'clonal expansion' by subtracting duplicate identical mutations recovered from the same animals, the proportions of mutation classes recovered from control and DCA-exposed mice are still significantly different (P ϭ 0.03, hypergeometric test). Tables III and IV show the specific mutations recovered from control and treated mouse liver. Single base substitutions comprised 78.71% of the background mutations, with 59.57% being transitions and 19.14% being transversions. Seven of the base substitutions resulted in stop codons (Table III) . The mutation spectrum recovered from control mice had a high frequency of G:C→A:T transitions (53.19%), with about half of these mutations occurring at CpG sites. It has been reported (10) that CpG dinucleotides are preferentially involved in background mutations in this system. Although most mutations recovered from the controls were base substitutions, five frameshifts of either ϩ1 or -1 base were noted. Three deletions of 6, 11 and 300 bases and one complex mutation were also recovered (Table III) . In DCA-treated mice, single base substitutions comprised 88.52% of the mutations, with 47.54% being transitions and 40.98% being transversions. Of the 20 G:C→A:T transitions, eight were at CpG sites, implying that these particular mutations were not induced preferentially by DCA treatment. Nine of the base substitutions resulted in the original amino acid being changed to a stop codon (Table IV) .
Mutations recovered from mouse liver
In contrast to the mutation spectrum obtained from control 2103 animals, there was a high frequency of mutations at T:A sites in the DCA-treated animals. The controls had 19.15% of total mutants at T:A sites, whereas the treated had 32.79% of total mutations at these sites. The A:T→T:A transversion at base 1004 is the only mutation of this class occurring in both the control and treated mutation spectra. Other classes of mutations that were recovered from DCA-exposed mice included five frameshifts of -1 or ϩ1 base, a 3 base deletion resulting in the loss of a tyrosine and a large deletion of 143 bases.
Discussion
Mutagenicity of DCA in vitro and in vivo
There are several studies that have demonstrated the hepatocarcinogenicity of DCA in mice when administered in drinking water. Herren-Freund et al. (4) found that after 61 weeks of exposure to DCA-treated drinking water, hepatocellular carcinomas were found in 81% of animals. Prior initiation of the animals with ethylnitrosourea did not result in a greater incidence of tumors. They concluded that DCA was acting as a complete carcinogen. A later study (2) confirmed that DCA was a complete carcinogen for male B6C3F1 mice. However, they suggested that the increased incidence of tumors in these mice might be due to DCA promoting the outgrowth of already initiated cells and that DCA did not possess significant genotoxic activity to initiate tumors directly. Bull et al. (3) also suggested that DCA simply stimulated the growth of cells that were already initiated. Synder et al. (14) noted that spontaneous apoptosis in hepatocytes of male B6C3F1 mice treated with DCA for 5-30 days was reduced. They postulated that the carcinogenic mechanism of DCA may involve suppression of the ability of the liver to remove initiated cells by apoptosis, resulting in outgrowth of initiated cells and tumor formation. Gunz et al. (15) investigated whether the Big Blue ® transgenic mouse assay could detect non-genotoxic carcinogens. Heptachlor, di(2-ethylhexyl)phthalate and phenobarbital were given for 4 months at dose levels that were positive in the 2 year cancer bioassay. These chemicals did not give rise to an increased level of lacI mutations in livers of C57BL/6 mice. The detection of lacI -mutants induced by DCA different from mutations found in control animals suggests that the hepatocarcinogenic mechanism of DCA has a genotoxic component to it, although this may not be due to direct binding of DCA to DNA. Recently, a report has been published indicating that DCA is not mutagenic in various standard mutagenicity assays (16) . The authors note that their test material, which is pharmaceutical grade, has fewer impurities than materials tested in previous reports, thus explaining the difference between their results and those of other researchers. However, the purity of the DCA used in our experiments and in those of others (6,9) was Ͼ99%. The conclusion drawn by the authors that the quality of the chemical is the reason for no response does not fully explain the differences in the results. Nor do the authors discuss the recent in vivo results demonstrating a hepatocarcinogenic response of mice to DCA.
A previous report demonstrated the potential genotoxicity of DCA in vitro (6) . It was found that DCA was a weak inducer of prophage λ in E.coli in the microscreen prophage GCTGATTGGCGTTGC  T→A  225  1  Val→Asp  ATTGGCGTTGCCACC  C→T  270  2  Ala→Val  ATTGTCGCGGCGATT  C→A  318  1  Ser→UAG GTGGTGTCGATGGTA  G deleted  319  1  Frameshift TGGTGTCGATGGTAG  A→T  320  1  Met→Leu GGTGTCGATGGTAGA  G deleted  326  1  Frameshift GATGGTAGAACGAAG  A deleted  350  1  Frameshift AGCCTGTAAAGCGGC  G→A  381  1  Arg→His  GCGCAACGCGTCAGT  T→G  406  1  Tyr→UAG TTAACTATCCGCTGG  T→C  471  1  Leu→Pro  TTATTTCTTGATGTC  A insertion 496  1  Frameshift ACCCATCϪAACAGTA  T→C  549  1  Leu→Pro  GAGCATCTGGTCGCA  T→C  582  1  Leu→Ser  GCGCTGTTAGCGGGC  G→A  588  1  Gly→Asp  TTAGCGGGCCCATTA  C→A  606  1  Ser→UAG TCTGTCTCGGCGCGT  G→T  677  1  Glu→UAA GGAACGGGAAGGCGA  G→A  681  1  Gly→Asp  CGGGAAGGCGACTGG  C deleted  699  1  Frameshift GCCATGTCCGGTTTT  T→A  774  1  Met→Lys  GATCAGATGGCGCTG  G→A  782  1  Gly→Ser  GGCGCTGGGCGCAAT  G→T  783  1  Gly→Val  GCGCTGGGCGCAATG  C→A  786  1  Ala→Gln  CTGGGCGCAATGCGC  T→A  840  1  Val→Gln  TCGGTAGTGGGATAC  T→C  869  1  Cys→Arg  CAGCTCATGTTATAT  A→G  873  1  Tyr→Cys  TCATGTTATATCCCG  T→A  930  1  Val→Glu  ACCAGCGTGGACCGC  A→T  1004  1  Arg→UGA GGTGAAAAGAAAAAC  C→A  1011  2  Thr→Asn  AGAAAAACCACCCTG  Deletion  1100→1243 1  N/A  ACTGGAA-TTACGGA  G→T  1200  1  N/A  TGGAATTGTGAGCGG  G→A  1206  2  N/A  TGTGAGCGGATAACA  C→T  1222  1  N/A  TTTCACACAGGAAAC induction assay, producing a 3-to 4-fold increase in p.f.u./ plate relative to background. When DCA (Ϯ S9) was evaluated in the vapor phase on Salmonella TA100 it produced a 3-fold increase in revertants/plate relative to the background. However, DCA has been shown to be negative in the standard plate incorporation assay (5) . Several researchers have examined the in vivo genotoxicity of DCA. In examining the capability of DCA to induce DNA strand breaks in rodent liver cells in vivo, Chang et al. (7) found that DCA induced a small amount of strand breakage at 4 h but not at 1 h. Continuous exposure of male B6C3F1 mice to 5 g/l DCA in drinking water for 7 and 14 days did not induce hepatic DNA strand breaks. These results are in direct contrast to those obtained by Nelson and Bull (8) , who reported a dose-dependent increase in both rat and mouse liver DNA strand breaks induced by DCA. Fuscoe et al. (9) have shown that DCA may be a weak inducer of chromosome damage when provided to mice in drinking water under conditions that produce tumors. Their results showed a doserelated increase in the frequency of micronucleated polychromatic erythrocytes after subchronic exposure to DCA for 9 days, as well as an increase in the frequency of micronucleated normochromatic erythrocytes in mice treated with 3.5 g/l DCA following 10 weeks of exposure.
Mutation spectrum of DCA and mutational mechanisms
Mutational analysis of livers from male transgenic B6C3F1 mice treated with DCA for 60 weeks showed a spectrum with three types of mutations dominating. Although G:C→A:T transitions comprised the highest percentage of mutants obtained from DCA-treated animals, this was lower than the percentage recovered from control animals. Therefore, DCA did not induce this particular class of mutation in mouse livers. There was a shift in the frequency of other classes of mutations found in livers from DCA-treated animals. The G:C→T:A transversions, and transitions and transversions at T:A sites were recovered more frequently among DCA-treated animals than among control animals.
Several researchers have examined K-and H-ras protooncogene activation in tumors from B6C3F1 mice exposed to DCA in order to understand the mechanism of DCA-induced hepatocarcinogenesis. Anna et al. (17) found a decrease in codon 61 of CAA→AAA and an increase in CAA →CTA base substitutions. They concluded that oncogene activation was not the primary mechanism of action of DCA because ras activation was absent in many of the liver neoplasms studied. Another study (18) found that there was a shift in the frequency at which different mutations occurred in codon 61 of H-ras. Tumors with H-ras mutations from DCA-treated mice showed fewer CAA→AAA mutations than spontaneous tumors and an increase in CAA→CGA as well as CAA→CTA mutations. The mutation spectra obtained from spontaneous tumors did not show any T:A→ A:T substitutions, however, others have detected this mutation in spontaneous tumors (17) . The incidence of H-ras mutations in spontaneous tumors and in tumors from DCA-treated mice was equal. The authors suggested that DCA may be acting as a weak genotoxin because of the shift in mutation spectrum and because the percentage of mice with tumors as well as the multiplicity of tumors/mouse increased with DCA treatment. Our mutation data are similar to the data obtained from these investigations of ras proto-oncogene activation in the livers of animals treated with DCA because T:A→A:T and T:A→C:G base substitutions were also increased in the lacI gene in B6C3F1 mouse livers.
The mutation spectrum induced by DCA has been examined in only one other system, strain TA100 of Salmonella (6) . In that study DCA induced mainly G:C→A:T transitions. Unfortunately, base substitutions occurring primarily at the target sequence CC/GG are detected with this assay. Therefore, other classes of mutations, especially those at T:A sites, cannot be evaluated with this particular strain of Salmonella. The authors postulated that the mechanism of action of DCA was due to formation of etheno adducts on cytosine, resulting in DNA polymerase misincorporating an adenine opposite the etheno adduct. This could explain the predominance of G:C→A:T transitions in both the Salmonella and transgenic mouse mutation spectra, but it does not explain the increase in mutations found at T:A sites. It has been previously suggested that a possible mechanism that explains the mutations at T:A sites is deamination of adenine to hypoxanthine, resulting in a C or an A being misincorporated in the complementary strand upon replication (18) .
Conclusions
The present study demonstrates the mutagenic activity associated with DCA treatment in transgenic B6C3F1 mouse liver in vivo. The results show that DCA at 3.5 g/l induces an increase in mutant frequency in livers of male B6C3F1 mice treated for 4-60 weeks. The resulting mutation spectra show similarities with the DCA-induced mutation spectra obtained from H-ras codon 61 and in Salmonella TA100. These data support the earlier in vivo reports establishing the complete hepatocarcinogenicity of DCA in mouse liver. Although there is no direct evidence that DCA is a causative agent in human cancer, the possibility that the mechanism of action of DCA in producing liver tumors has a genotoxic component may increase concern for DCA carcinogenicity in humans. The possibility that DCA may induce specific DNA damage must be studied further in order to elucidate the mechanism of action of DCA hepatocarcinogenesis.
